248 related articles for article (PubMed ID: 9228472)
21. The fluconazole era: management of hematogenously disseminated candidiasis in the nonneutropenic patient.
Kramer KM; Skaar DJ; Ackerman BH
Pharmacotherapy; 1997; 17(3):538-48. PubMed ID: 9165556
[TBL] [Abstract][Full Text] [Related]
22. Risk factors for candidemia-related mortality at a medical center in central Taiwan.
Cheng YR; Lin LC; Young TG; Liu CE; Chen CH; Tsay RW
J Microbiol Immunol Infect; 2006 Apr; 39(2):155-61. PubMed ID: 16604249
[TBL] [Abstract][Full Text] [Related]
23. The changing epidemiology of invasive candidiasis: Candida glabrata and Candida krusei as the leading causes of candidemia in hematologic malignancy.
Hachem R; Hanna H; Kontoyiannis D; Jiang Y; Raad I
Cancer; 2008 Jun; 112(11):2493-9. PubMed ID: 18412153
[TBL] [Abstract][Full Text] [Related]
24. The changing face of candidemia: emergence of non-Candida albicans species and antifungal resistance.
Nguyen MH; Peacock JE; Morris AJ; Tanner DC; Nguyen ML; Snydman DR; Wagener MM; Rinaldi MG; Yu VL
Am J Med; 1996 Jun; 100(6):617-23. PubMed ID: 8678081
[TBL] [Abstract][Full Text] [Related]
25. Fluconazole plus amphotericin B combinations are not contraindicated and may add benefit for the treatment of candidemia.
Odds FC
Clin Infect Dis; 2003 May; 36(10):1229-31. PubMed ID: 12746766
[No Abstract] [Full Text] [Related]
26. [Epidemiology of fungemia in a university hospital; therapeutic incidence].
Pavese P; Brion JP; Lebeau B; Grillot R; Ambroise-Thomas P
Pathol Biol (Paris); 1999 May; 47(5):579-83. PubMed ID: 10418046
[TBL] [Abstract][Full Text] [Related]
27. Treatment of invasive candidal infections: systematic review and meta-analysis.
Gafter-Gvili A; Vidal L; Goldberg E; Leibovici L; Paul M
Mayo Clin Proc; 2008 Sep; 83(9):1011-21. PubMed ID: 18775201
[TBL] [Abstract][Full Text] [Related]
28. Initial antifungal strategy does not correlate with mortality in patients with candidemia.
Murri R; Scoppettuolo G; Ventura G; Fabbiani M; Giovannenze F; Taccari F; Milozzi E; Posteraro B; Sanguinetti M; Cauda R; Fantoni M
Eur J Clin Microbiol Infect Dis; 2016 Feb; 35(2):187-93. PubMed ID: 26634352
[TBL] [Abstract][Full Text] [Related]
29. Fluconazole vs. amphotericin B for the treatment of neonatal fungal septicemia: a prospective randomized trial.
Driessen M; Ellis JB; Cooper PA; Wainer S; Muwazi F; Hahn D; Gous H; De Villiers FP
Pediatr Infect Dis J; 1996 Dec; 15(12):1107-12. PubMed ID: 8970221
[TBL] [Abstract][Full Text] [Related]
30. Invasive candidiasis treated in the intensive care unit: observations from a randomized clinical trial.
DiNubile MJ; Lupinacci RJ; Strohmaier KM; Sable CA; Kartsonis NA
J Crit Care; 2007 Sep; 22(3):237-44. PubMed ID: 17869975
[TBL] [Abstract][Full Text] [Related]
31. Secular trend in candidemia and the use of fluconazole in Finland, 2004-2007.
Poikonen E; Lyytikäinen O; Anttila VJ; Koivula I; Lumio J; Kotilainen P; Syrjälä H; Ruutu P
BMC Infect Dis; 2010 Oct; 10():312. PubMed ID: 21029444
[TBL] [Abstract][Full Text] [Related]
32. Candidemia in a tertiary care cancer center: in vitro susceptibility and its association with outcome of initial antifungal therapy.
Antoniadou A; Torres HA; Lewis RE; Thornby J; Bodey GP; Tarrand JP; Han XY; Rolston KV; Safdar A; Raad II; Kontoyiannis DP
Medicine (Baltimore); 2003 Sep; 82(5):309-21. PubMed ID: 14530780
[TBL] [Abstract][Full Text] [Related]
33. Nosocomial candidemia in a tertiary care hospital in Saudi Arabia.
Bukharie HA
Mycopathologia; 2002; 153(4):195-8. PubMed ID: 12014479
[TBL] [Abstract][Full Text] [Related]
34. Fungaemia caused by Candida glabrata with reduced susceptibility to fluconazole due to altered gene expression: risk factors, antifungal treatment and outcome.
Tumbarello M; Sanguinetti M; Trecarichi EM; La Sorda M; Rossi M; de Carolis E; de Gaetano Donati K; Fadda G; Cauda R; Posteraro B
J Antimicrob Chemother; 2008 Dec; 62(6):1379-85. PubMed ID: 18782778
[TBL] [Abstract][Full Text] [Related]
35. Management of invasive candidal infections: results of a prospective, randomized, multicenter study of fluconazole versus amphotericin B and review of the literature.
Anaissie EJ; Darouiche RO; Abi-Said D; Uzun O; Mera J; Gentry LO; Williams T; Kontoyiannis DP; Karl CL; Bodey GP
Clin Infect Dis; 1996 Nov; 23(5):964-72. PubMed ID: 8922787
[TBL] [Abstract][Full Text] [Related]
36. [Candidemia: a never ceasing challenge].
Muñoz García de Paredes P
Rev Clin Esp; 1997 Dec; 197(12):795-7. PubMed ID: 9477668
[No Abstract] [Full Text] [Related]
37. Antifungal activity of voriconazole (UK-109,496), fluconazole and amphotericin B against hematogenous Candida krusei infection in neutropenic guinea pig model.
Ghannoum MA; Okogbule-Wonodi I; Bhat N; Sanati H
J Chemother; 1999 Feb; 11(1):34-9. PubMed ID: 10078778
[TBL] [Abstract][Full Text] [Related]
38. Candida and candidaemia. Susceptibility and epidemiology.
Arendrup MC
Dan Med J; 2013 Nov; 60(11):B4698. PubMed ID: 24192246
[TBL] [Abstract][Full Text] [Related]
39. [Clinical aspects and prognosis of candidemia, a 6-year retrospective study].
Bregenzer T; Evison-Eckstein AC; Frei R; Zimmerli W
Schweiz Med Wochenschr; 1996 Oct; 126(43):1829-33. PubMed ID: 9005522
[TBL] [Abstract][Full Text] [Related]
40. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study.
Garey KW; Rege M; Pai MP; Mingo DE; Suda KJ; Turpin RS; Bearden DT
Clin Infect Dis; 2006 Jul; 43(1):25-31. PubMed ID: 16758414
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
